Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 23 Breast Neoplasms 10 Lung Neoplasms 8 Squamous Cell Carcinoma of Head and Neck 6 Neoplasms 5 Head and Neck Neoplasms 5 Esophageal Squamous Cell Carcinoma 5 Carcinoma, Squamous Cell 5 Neoplasm Metastasis 4 Colorectal Neoplasms 4 Stomach Neoplasms 3 Prostatic Neoplasms 3 Multiple Myeloma 3 Lymphoma 3 Esophageal Neoplasms 3 Urinary Bladder Neoplasms 2 Non-small-cell Lung Cancer With Somatic EGFR Mutations 2 Hematologic Neoplasms 2 Glioma 2 Adenocarcinoma of Lung 2 Uterine Neoplasms 1 Uterine Cervical Neoplasms 1 Urologic Neoplasms 1 Urethral Neoplasms 1 Ureteral Neoplasms 1 Unilateral HER2 Positive Breast Cancer 1 Triple Negative Breast Neoplasms 1 Thyroid Neoplasms 1 Squamous Cell Cancers of the Head and Neck 1 Solid Tumors 1

Interventions

Nivolumab 3 palbociclib 2 Ipilimumab 2 Imatinib Mesylate 2 relatlimab 1 pembrolizumab 1 camrelizumab 1 apatinib 1 Specimen Handling 1 Radiotherapy 1 Radiation 1 Protons 1 Proton Therapy 1 Pemetrexed 1 Magnetic Resonance Spectroscopy 1 Immunoglobulin G 1 Disulfides 1 Dasatinib 1 Cetuximab 1 CTLA-4 Antigen 1 Afatinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Chordoma × Afatinib × Clear all

NCT03083678 2025-02-13

Afatinib in Locally Advanced and Metastatic Chordoma

Leiden University Medical Center

Phase 2 Completed

Chordoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡